These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34111559)

  • 21. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair.
    Stegeman H; Span PN; Cockx SC; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH; Bussink J
    Radiat Res; 2013 Oct; 180(4):414-21. PubMed ID: 24059677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
    Feng FY; Lopez CA; Normolle DP; Varambally S; Li X; Chun PY; Davis MA; Lawrence TS; Nyati MK
    Clin Cancer Res; 2007 Apr; 13(8):2512-8. PubMed ID: 17438112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.
    Dickreuter E; Eke I; Krause M; Borgmann K; van Vugt MA; Cordes N
    Oncogene; 2016 Mar; 35(11):1353-62. PubMed ID: 26073085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis.
    Zhang LT; Ke LX; Wu XY; Tian HT; Deng HZ; Xu LY; Li EM; Long L
    Biomed Res Int; 2022; 2022():7295458. PubMed ID: 35601150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
    Ansell A; Jedlinski A; Johansson AC; Roberg K
    J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
    Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
    Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
    Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M
    Int J Cancer; 2019 Aug; 145(3):748-762. PubMed ID: 30694565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
    Zhou XY; Shu XM
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
    Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
    Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
    Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL
    Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity.
    Hama T; Nagesh PK; Chowdhury P; Moore BM; Yallapu MM; Regner KR; Park F
    JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34806647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
    Kriegs M; Kasten-Pisula U; Rieckmann T; Holst K; Saker J; Dahm-Daphi J; Dikomey E
    DNA Repair (Amst); 2010 Aug; 9(8):889-97. PubMed ID: 20615764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
    Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
    Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.